ESTROGEN BLOCKERS MARKET ANALYSIS

The global estrogen blockers market size was valued at US$ 15.02 billion in 2023 and is expected to reach US$ 23.34 billion by 2030, growing at a CAGR of 6.5% from 2023 to 2030.

• The growth of the global estrogen blockers market is being driven by the rising prevalence of breast cancer, prostate cancer, and other hormonal disorders. Estrogen blockers are used to treat these conditions by preventing the production or action of estrogen.
• In addition, the increasing demand for novel drug delivery mechanisms and the growing preference for personalized medicine are also driving the growth of the market.
• However, the high cost of estrogen blockers and the potential side effects associated with their use are restraining the growth of the market.
• The global estrogen blockers market is segmented by product type, application, distribution channel and region.
• By product type, the market is segmented into aromatase inhibitors, selective estrogen receptor modulators (SERMs), Estrogen Receptor Downregulators (ERDs) and others. Aromatase inhibitors are the leading segment of the market, accounting for a major share of the market in 2022. This is due to the increasing use of aromatase inhibitors to treat breast cancer.

Global Estrogen Blockers Market Regional Insights

• North Americais the leading region in the estrogen blockers market, accounting for a major share of 35.2% market in 2023. This is due to the high prevalence of breast cancer and prostate cancer in the region.
• Europeis the second-leading region in the estrogen blockers market, accounting for a significant share of 26.5 market in 2023. This is due to the high awareness of estrogen blockers in the region and the increasing demand for personalized medicine.
• Asia-Pacificis the third-leading region in the estrogen blockers market,  accounting for a significant share of 19.7 market in 2023. This is due to the rising prevalence of breast cancer and prostate cancer in the region, and the increasing demand for novel drug delivery mechanisms.

Analyst View: The estrogen blockers market has strong potential for growth, driven by rising awareness about hormonal treatments and early menopause. The increasing incidence of breast cancer and hormonal imbalance disorders will continue to boost the demand for drugs that inhibit estrogen activity in the patient’s body. However, side effects associated with long-term usage of blockers, such as hot flashes, night sweats, and vaginal dryness, remain a challenge for widespread customer acceptance.

Figure 1. Global Estrogen Blockers Market Share (%), by Region, 2023

To learn more about this report, request a free sample copy

Global Estrogen Blockers Market Drivers

• Increasing Prevalence of Hormone-related Disorders: Estrogen blockers are primarily used in the treatment of hormone-related disorders such as breast cancer, endometriosis, and polycystic ovary syndrome (PCOS). As the prevalence of these disorders continues to rise globally, the demand for estrogen blockers increases, thereby driving the market growth.
• Growing Awareness and Screening Initiatives: There is a growing awareness among individuals about the importance of early detection and screening of hormone-related disorders. Governments and healthcare organizations are actively promoting screening initiatives, which has led to an increased diagnosis of these disorders. Consequently, the demand for estrogen blockers as a treatment option has increased.
• Advancements in Drug Development: The pharmaceutical industry is investing in research and development to develop more effective and efficient estrogen blockers. This has resulted in the introduction of new and improved drugs with enhanced therapeutic efficacy and reduced side effects. The availability of advanced estrogen blockers has expanded the market by providing better treatment options.
• Increasing Adoption of Hormone Replacement Therapy (HRT): Hormone replacement therapy, which involves the administration of estrogen to address symptoms of menopause, is becoming more popular among women. However, HRT can also increase the risk of certain hormone-related disorders. As a result, estrogen blockers are often prescribed alongside HRT to mitigate the potential risks. The growing adoption of HRT contributes to the demand for estrogen blockers.

Global Estrogen Blockers Market Opportunities

• Expansion of Indications: While estrogen blockers are commonly used in the treatment of hormone-related disorders such as breast cancer and endometriosis, there is an opportunity to explore new indications and expand their usage. Research and development efforts can focus on identifying and validating the potential of estrogen blockers in treating other conditions related to hormonal imbalances, thereby expanding the market.
• Increasing Demand in Emerging Markets: The demand for estrogen blockers is not limited to developed markets; emerging markets present significant growth opportunities. The need for cutting-edge therapeutic options, such as estrogen blockers, is rising in emerging economies as healthcare facilities and awareness improve. Expanding market penetration in these regions can lead to substantial growth and revenue generation.
• Combination Therapies: Estrogen blockers can be used in combination with other drugs or treatment modalities to enhance their efficacy or reduce side effects. Exploring and developing combination therapies can provide new opportunities in the estrogen blockers market. For instance, combining estrogen blockers with targeted therapies or immunotherapies in the treatment of certain cancers may yield synergistic effects and improved patient outcomes.
• Personalized Medicine Approaches: Personalized medicine aims to tailor treatments to individual patients based on their unique characteristics, including genetic and hormonal profiles. Estrogen blockers can play a crucial role in personalized medicine by targeting specific hormone-related conditions in a personalized manner. Developing and promoting personalized medicine approaches can create new avenues for growth and differentiation in the estrogen blockers market.

Global Estrogen Blockers Market Trends

• Targeted Therapies: There is a growing emphasis on developing targeted therapies in the field of estrogen blockers. Targeted therapies aim to selectively inhibit specific molecular pathways or receptors involved in hormone-related disorders, such as breast cancer. This trend enables more precise and effective treatment options, minimizing adverse effects on healthy tissues and improving patient outcomes.
• Hormone Receptor Modulators: Hormone receptor modulators, a class of estrogen blockers, are gaining attention in the market. These drugs can selectively modulate the activity of hormone receptors, either by blocking or stimulating them, depending on the therapeutic indication. This flexibility allows for a more nuanced approach in managing hormone-related conditions and offers potential benefits in terms of efficacy and side effect profiles.
• Development of Novel Formulations: Pharmaceutical companies are investing in the development of novel formulations to improve drug delivery and patient convenience. For example, sustained-release formulations, transdermal patches, and subcutaneous implants are being explored to provide controlled and extended drug release, reducing the frequency of administration and improving patient compliance.
• Increasing Focus on Combination Therapies: Combination therapies involving estrogen blockers are becoming more prevalent. Researchers are investigating the synergistic effects of combining estrogen blockers with other drugs, such as chemotherapy agents or immunotherapies, to enhance treatment outcomes. Combination therapies have the potential to improve response rates, delay drug resistance, and increase overall survival rates in hormone-related disorders.

Global Estrogen Blockers Market Restraints

• Side Effects and Safety Concerns: Estrogen blockers, like any medication, can be associated with side effects and safety concerns. Common side effects may include hot flashes, mood swings, joint pain, and changes in cholesterol levels. In some cases, long-term use of estrogen blockers may increase the risk of bone loss and cardiovascular complications. Safety concerns and potential side effects can affect patient compliance and acceptance of estrogen blockers.
• Regulatory Challenges: Regulatory requirements and approvals play a significant role in the pharmaceutical industry. The process of obtaining regulatory approvals for new estrogen blockers or expanded indications can be time-consuming and expensive. Strict regulations and complex approval processes can delay market entry and limit the availability of innovative estrogen blockers.
• Competition from Alternative Treatments: Estrogen blockers face competition from alternative treatment options. Depending on the indication, healthcare providers may choose other therapies such as surgery, radiation therapy, or hormonal therapies that work through different mechanisms. Alternative treatments may offer different benefits or be more established in certain conditions, posing a challenge to the adoption and market share of estrogen blockers.
• Patent Expirations and Generic Competition: As patents for existing estrogen blockers expire, generic versions and biosimilars can enter the market. Generic competition can lead to price erosion and reduced profit margins for branded estrogen blockers. The availability of lower-cost alternatives may also impact market share and revenue generation for original manufacturers.

Figure 2. Global Estrogen Blockers Market Share (%), by application, 2023

To learn more about this report, request a free sample copy

Recent Developments

Marketed Products

• Fulvestrant (Faslodex). Fulvestrant is a third-generation aromatase inhibitor that is approved for the treatment of advanced breast cancer in women who have already received other hormonal therapies. It is also being investigated for the prevention of breast cancer in women who are at high risk.
• Ospemert (Jemperli). Ospemert is a monthly subcutaneous injection that is approved for the treatment of advanced breast cancer in women who have already received other hormonal therapies. It is a selective estrogen receptor degrader (SERD), which means that it works by binding to and degrading the estrogen receptor.
• Trametinib (Mekinist). Trametinib is a kinase inhibitor that is approved for the treatment of advanced breast cancer in women who have a BRAF V600E mutation. It works by blocking the activity of the BRAF protein, which is involved in the growth of cancer cells.

Product Launch and Approval  

• On June 5, 2023, Pfizer Inc., a pharmaceutical company, announced that DUAVEE (conjugated estrogens/bazedoxifene), an estrogen-based menopause hormone therapy, was reissued in stock in the U.S., with improved packaging following a voluntary recall in May 2020. The recall was due to an issue with the packaging and was not based on any efficacy or safety concerns with the product itself.
• On May 13, 2023, Astellas Pharma Inc., a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved VEOZAHTM (fezolinetant) 45 mg once daily for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause. VEOZAH is the first nonhormonal neurokinin 3 (NK3) receptor antagonist approved to treat VMS due to menopause.
• In October 2021, the U.S. Food and Drug Administration (FDA) announced the approval of Eli Lilly and Company's, a pharmaceutical company, Verzenio (abemaciclib), in combination with endocrine therapy (tamoxifen or an aromatase inhibitor), for the adjuvant treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, early breast cancer (EBC) at high risk of recurrence and a Ki-67 score of ≥20% as determined by an FDA-approved test. Ki-67 is a marker of cellular proliferation. Verzenio is the first and only CDK4/6 inhibitor approved for this patient population.

Research & Development, Collaboration and

• In October 2022, AstraZeneca, a global pharmaceutical company, announced the positive results from the CAPItello-291 Phase III trial, with an aim to study capivasertib in combination with Faslodex (fulvestrant) that demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus placebo plus Faslodex in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-low or negative locally advanced or metastatic breast cancer, following recurrence or progression on or after endocrine therapy (with or without a CDK4/6 inhibitor).
• In November 2021, Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced the first clinical data from the Phase 1 dose-escalation portion of the ongoing Phase 1/2 clinical trial of OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) in development for the treatment of metastatic breast cancer and other women’s cancers.
• In July 2021, Arvinas, Inc., a pharmaceutical company and Pfizer Inc. announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC (proteolysis targeting chimera) estrogen receptor protein degrader. The estrogen receptor is a well-known disease driver in most breast cancers. ARV-471 is currently in a Phase 2 dose expansion clinical trial for the treatment of patients with estrogen receptor (ER) positive or human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) locally advanced or metastatic breast cancer.

Top companies in Global Estrogen Blockers Market

• Pfizer Inc.
• Novartis AG
• AstraZeneca PLC
• Eli Lilly and Company
• Merck & Co., Inc.
• Bristol Myers Squibb Company
• Sanofi S.A.
• AbbVie Inc.
• GlaxoSmithKline plc
• Olema Pharmaceuticals, Inc.
• Scorpion Therapeutics, Inc.
• Allorion Therapeutics Inc
• Carrick Therapeutics Limited
• Criterium, Inc.
• Hoffmann-La Roche

*Definition: Estrogen blockers, also known as anti-estrogens, are drugs that inhibit the effects of estrogen, a hormone that promotes the growth of some types of breast cancer cells. These drugs work by blocking the estrogen receptors on the cancer cells, preventing the hormone from attaching and signaling the cells to grow and divide.

There are two main types of estrogen blockers:

• Selective Estrogen Receptor Modulators (SERMs): These drugs bind to the estrogen receptors on cancer cells, blocking estrogen from attaching. However, they act like estrogen in some tissues, such as the bones and uterus. Tamoxifen is a commonly used SERM.
• Aromatase Inhibitors (AIs): These drugs work by lowering the amount of estrogen in the body. They do this by blocking the enzyme aromatase, which converts other hormones into estrogen. Examples of AIs include anastrozole, letrozole, and exemestane.

Estrogen blockers are often used in the treatment of hormone receptor-positive breast cancer, which is the most common type of breast cancer. They can be used in premenopausal and postmenopausal women, as well as in men with breast cancer.